Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining personalized medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to personalized medicine – to de
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 9, 2017--
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief
Executive Officer and President, Patrick J. Mahaffy, will present at the
35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10,
2017 at 2:30 PM Pacific Time. The conference will be held at the Westin
St. Francis Hotel in San Francisco.
A live webcast of the presentation and breakout session can be accessed
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 4, 2017--
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the
underwriters of its recently announced public offering of its common
stock have exercised in full their option to purchase an additional
The offering, including the sale of the additional shares, is expected
to close on January 9, 2017, subject to customary closing conditions.
Clovis Oncology intends to use t...
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 3, 2017--
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an
underwritten public offering of 5,000,000 shares of its common stock at
$41.00 per share, before underwriting discounts and commissions. The
size of the offering was upsized from $175 million to $205 million. In
addition, the underwriters have a 30-day option to purchase up to an
additional 750,000 shares of common stock from Clovis Oncol...
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.